Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 03-2020 | 12-2019 | 09-2019 | 06-2019 | 03-2019 | |
| Sales | 2,347 | 2,610 | 2,268 | 2,763 | 2,429 |
| Cost of Goods | 1,388 | 1,656 | 1,328 | 1,726 | 1,726 |
| Gross Profit | 959 | 954 | 940 | 1,037 | 704 |
| Operating Expenses | 6,078 | 5,126 | 5,786 | 4,213 | 4,984 |
| Operating Income | -5,119 | -4,172 | -4,846 | -3,176 | -4,281 |
| Interest Expense | 132 | 66 | 125 | 127 | 21 |
| Other Income | -1,659 | 35 | 20 | 22 | -89 |
| Pre-tax Income | -6,910 | -4,203 | -4,951 | -3,281 | -4,391 |
| Income Tax | -15 | -2 | 6 | 4 | 4 |
| Net Income Continuous | -6,895 | -4,201 | -4,957 | -3,285 | -4,395 |
| Net Income | $-6,895 | $-4,201 | $-4,957 | $-3,285 | $-4,395 |
| EPS Basic Total Ops | -0.20 | -0.20 | -0.20 | -0.10 | -0.20 |
| EPS Basic Continuous Ops | -0.20 | -0.20 | -0.20 | -0.10 | -0.20 |
| EPS Diluted Total Ops | -0.20 | -0.20 | -0.20 | -0.10 | -0.20 |
| EPS Diluted Continuous Ops | -0.20 | -0.20 | -0.20 | -0.10 | -0.20 |
| EBITDA(a) | $-6,639 | $-3,997 | $-4,676 | $-3,011 | $-4,245 |